Skip to main content
Premium Trial:

Request an Annual Quote

Aureus Pharma, MDL Isentris, Russia’s Interior Ministry, Stony Brook University, SRI International, BioCyc, UCB, Genedata, Rosetta Biosoftware, Waters, NIH

Aureus Pharma Joins MDL Isentris Alliance
Elsevier MDLsaid this week that Aureus Pharma has joined the MDL Isentris Alliance. In addition, Aureus will deliver its content in the MDL Direct format, which will enable MDL Isentris customers to access Aureus content via MDL’s informatics system.
Content from Aureus includes experimental activity data mined from literature related to drug classes including GPCRs, ion channels, and kinases, as well as drug-safety topics like ADME and drug-drug interactions and the hERG channel.
The partnership will allow Aureus to supplement its own commercial knowledge databases with the MDL data cartridge.
The MDL Direct chemistry search engine is designed to perform on databases with over 5 million reactions and at least 20 million structures.

Report: Russia to Create Genome Data Bank for Criminals
Several news organizations reported this week that Russia’s Interior Ministry has drafted a law to set up a genome data bank to speed searches for criminals in the country.
Russian newspaper [Kommersant cited medical experts saying the ministry’s plans posed a threat for “biological security,” but also reported that the law, if adopted, is designed to fight not only standard crime but terrorism and “extremism,” and would simplify the task of identifying bodies via DNA analysis.

Consortium Hopes to Put New York on the Computational Biology Map
Several universities in New York this week proposed to create a statewide consortium intendedto put the state on the “forefront” of computational biology.
Robert McGrath, provost and vice president for Brookhaven Laboratory Affairs at Stony Brook University, is spearheading the effort, which is intended to “take a coordinated approach to the development and application for computational sciences, especially computational biology,” according to a statement.
The proposed consortium would be supported by an IBM Blue Gene/L supercomputer installed at Brookhaven National Laboratory with funding from New York State, as well as a supercomputing center currently being installed at Rensselaer Polytechnic Institute. The installation offers Blue Gene/L as well as Opteron and PowerPC clusters.
The proposed consortium currently includes Stony Brook, Brookhaven, Columbia University, New York University, Rensselaer Polytechnic Institute, the University of Albany, the University at Buffalo, and Cornell University.

SRI International to Host BioCyc Tutorial at ICSB
SRI International will present a tutorial on “computational analyses across the BioCyc collection of pathway/genome databases” Oct. 1 during the International Conference on Systems Biology at Long Beach, Calif.
Students will learn how to perform computational analyses across the BioCyc collection of pathways and genome databases.
The tutorial will cover the methodologies used to create BioCyc, a description of the database schema and ontologies behind BioCyc, and descriptions of application programming interfaces that are available to query BioCyc.
Students attending should have basic familiarity with programming and databases as well as concepts in biology and metabolic pathways.
Further information is available here.

UCB to Use Genedata Software to Manage Drug Target Information
Genedata said this week that biopharmaceutical firm UCB will use its Phylosopher and Expressionist platforms to support its drug-discovery research in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders, and oncology.
Researchers at UCB’s sites in the UK and Belgium will use the software.
Financial terms of the agreement were not disclosed.

Rosetta Biosoftware to Make Elucidator Compatible With Waters' Mass Specs
Waters and Rosetta Biosoftware said this week that they will integrate Rosetta's software with two of Waters' mass spectrometers.
Terms of the deal call for the companies to make Rosetta Biosoftware's Elucidator software for protein expression data management compatible with Waters' Q-Tof Premier and Synapt high-definition mass spectrometers.

NIH Releases GAIN Study Data, Details Data-Access Procedure
The National Institutes of Health announced last week that it has released the first data from the Genetic Association Information Network, or GAIN, project, via the dbGAP database at the National Center for Biotechnology Information.
In a notice released on Friday, the NIH announced the availability of the data and outlined the process under which researchers can apply for access to GAIN project datasets.
GAIN is a public-private genome-wide association study project coordinated by the NIH and the Foundation for the NIH. FNIH awarded the first grants under the effort last October.
Last week, NIH released the data through GAIN dbGaP, the database of Genotype and Phenotype, which offers two levels of access: summary-level data that is available to anyone with no restrictions; and individual-level data that requires preauthorization.
Researchers can request access to the individual-level data from GAIN studies through the dbGaP data access request system. Further information about the process is available here.
Summary-level data is already available, and NIH said it expects to begin releasing individual-level data by June 9.

Filed under

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.